

PMSF

Catalog No: tcsc2617



Available Sizes

Size: 100mg

Size: 500mg



Specifications

CAS No:

329-98-6

Formula:

$C_7H_7FO_2S$

Pathway:

Metabolic Enzyme/Protease

Target:

Cathepsin

Purity / Grade:

>98%

Solubility:

DMSO : 20 mg/mL (114.82 mM; Need ultrasonic); H₂O :

Alternative Names:

Phenylmethanesulfonyl fluoride;Benzylsulfonyl fluoride

Observed Molecular Weight:

174.19


Product Description

PMSF is an irreversible **serine/cysteine protease** inhibitor.

In Vitro:

PMSF (2 mM) inhibits carbachol-stimulated inositol phosphate accumulation in the presence of Li^+ by only 15%-19%. PMSF inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown^[1]. PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form *T. brucei*. PMSF inhibits the formation of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhibits GPI acylation and ethanolamine phosphate addition in procyclic trypanosomes but not in HeLa cells^[2].

In Vivo: PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose-responsive increase in % MPE in the tail-flick latency evaluation, but fails to produce a clear dose-responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED_{50} values of 86, 224 and 206 mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!